India, Sept. 8 -- Crescent Biopharma, Inc. (CBIO), a clinical-stage biotechnology company, is scheduled to present at the 2026 Cantor Global Healthcare Conference on September 10, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.
Crescent Biopharma's clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as antibody-drug conjugates (ADCs) including CR-002 and CR-003.
Near Term Milestones
The company highlighted the following milestones in its recent second-quarter financial results.
- Enrollment is progressing in the ASCEND Phase 1/2 global clinical trial evaluating CR-001, in multiple solid tumour types in first-line and previously treated patients.
- In...